Cyclooxygenase-2 and epidermal growth factor receptor

Pharmacologic targets for chemoprevention

Andrew J. Dannenberg, Scott M. Lippman, Jason R. Mann, Kotha Subbaramaiah, Raymond N. DuBois

Research output: Contribution to journalArticle

301 Citations (Scopus)

Abstract

Understanding the mechanisms underlying carcinogenesis provides insights that are necessary for the development of therapeutic strategies to prevent cancer. Chemoprevention, the use of drugs or natural substances to inhibit carcinogenesis, is a rapidly evolving aspect of cancer research. Evidence is presented that cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) are potential pharmacologic targets to prevent cancer. In this paper, we review key data implicating a causal relationship between COX-2, EGFR, and carcinogenesis and possible mechanisms of action. We discuss evidence of crosstalk between COX-2 and EGFR in order to strengthen the rationale for combination chemoprevention, and review plans for a clinical trial that will evaluate the concept of combination chemoprevention targeting COX-2 and EGFR.

Original languageEnglish (US)
Pages (from-to)254-266
Number of pages13
JournalJournal of Clinical Oncology
Volume23
Issue number2
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Chemoprevention
Cyclooxygenase 2
Epidermal Growth Factor Receptor
Carcinogenesis
Neoplasms
Clinical Trials
Research
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dannenberg, A. J., Lippman, S. M., Mann, J. R., Subbaramaiah, K., & DuBois, R. N. (2005). Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. Journal of Clinical Oncology, 23(2), 254-266. https://doi.org/10.1200/JCO.2005.09.112

Cyclooxygenase-2 and epidermal growth factor receptor : Pharmacologic targets for chemoprevention. / Dannenberg, Andrew J.; Lippman, Scott M.; Mann, Jason R.; Subbaramaiah, Kotha; DuBois, Raymond N.

In: Journal of Clinical Oncology, Vol. 23, No. 2, 2005, p. 254-266.

Research output: Contribution to journalArticle

Dannenberg, AJ, Lippman, SM, Mann, JR, Subbaramaiah, K & DuBois, RN 2005, 'Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention', Journal of Clinical Oncology, vol. 23, no. 2, pp. 254-266. https://doi.org/10.1200/JCO.2005.09.112
Dannenberg, Andrew J. ; Lippman, Scott M. ; Mann, Jason R. ; Subbaramaiah, Kotha ; DuBois, Raymond N. / Cyclooxygenase-2 and epidermal growth factor receptor : Pharmacologic targets for chemoprevention. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 2. pp. 254-266.
@article{dc086e605d77491ea70b852029fa5be5,
title = "Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention",
abstract = "Understanding the mechanisms underlying carcinogenesis provides insights that are necessary for the development of therapeutic strategies to prevent cancer. Chemoprevention, the use of drugs or natural substances to inhibit carcinogenesis, is a rapidly evolving aspect of cancer research. Evidence is presented that cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) are potential pharmacologic targets to prevent cancer. In this paper, we review key data implicating a causal relationship between COX-2, EGFR, and carcinogenesis and possible mechanisms of action. We discuss evidence of crosstalk between COX-2 and EGFR in order to strengthen the rationale for combination chemoprevention, and review plans for a clinical trial that will evaluate the concept of combination chemoprevention targeting COX-2 and EGFR.",
author = "Dannenberg, {Andrew J.} and Lippman, {Scott M.} and Mann, {Jason R.} and Kotha Subbaramaiah and DuBois, {Raymond N.}",
year = "2005",
doi = "10.1200/JCO.2005.09.112",
language = "English (US)",
volume = "23",
pages = "254--266",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Cyclooxygenase-2 and epidermal growth factor receptor

T2 - Pharmacologic targets for chemoprevention

AU - Dannenberg, Andrew J.

AU - Lippman, Scott M.

AU - Mann, Jason R.

AU - Subbaramaiah, Kotha

AU - DuBois, Raymond N.

PY - 2005

Y1 - 2005

N2 - Understanding the mechanisms underlying carcinogenesis provides insights that are necessary for the development of therapeutic strategies to prevent cancer. Chemoprevention, the use of drugs or natural substances to inhibit carcinogenesis, is a rapidly evolving aspect of cancer research. Evidence is presented that cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) are potential pharmacologic targets to prevent cancer. In this paper, we review key data implicating a causal relationship between COX-2, EGFR, and carcinogenesis and possible mechanisms of action. We discuss evidence of crosstalk between COX-2 and EGFR in order to strengthen the rationale for combination chemoprevention, and review plans for a clinical trial that will evaluate the concept of combination chemoprevention targeting COX-2 and EGFR.

AB - Understanding the mechanisms underlying carcinogenesis provides insights that are necessary for the development of therapeutic strategies to prevent cancer. Chemoprevention, the use of drugs or natural substances to inhibit carcinogenesis, is a rapidly evolving aspect of cancer research. Evidence is presented that cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) are potential pharmacologic targets to prevent cancer. In this paper, we review key data implicating a causal relationship between COX-2, EGFR, and carcinogenesis and possible mechanisms of action. We discuss evidence of crosstalk between COX-2 and EGFR in order to strengthen the rationale for combination chemoprevention, and review plans for a clinical trial that will evaluate the concept of combination chemoprevention targeting COX-2 and EGFR.

UR - http://www.scopus.com/inward/record.url?scp=13744254574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13744254574&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.09.112

DO - 10.1200/JCO.2005.09.112

M3 - Article

VL - 23

SP - 254

EP - 266

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -